Strata Skin Sciences, Inc.

Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Strata Skin Sciences Inc. Third Quarter 2025 Financial Results and Corporate Update Conference Call. All participants will be in a listen-only mode. After today's presentation, there'll be an opportunity to ask questions. Please note today's event is being recorded. I would now like to turn the call over to Jules Abraham, Core of IRS, the company's investor relations firm. Please go ahead.

Thank you, Arielle. Good afternoon, everyone, and thank you all for participating in today's conference call. Earlier this afternoon, the company released its financial results for the quarter ended September 30th, 2025. A copy of that press release can also be found on the company's website at www.strataskinsciences.com under the Investors tab. Joining me on today's earnings call from Stratus Skin Sciences Management Team are Dr. Dola Raffaele, Chief Executive Officer, and John Gillings, Vice President of Finance. During this call, management will be making forward-looking statements, including statements that address Stratus Skin Sciences' expectations for future performance or operational results. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. More information about these risks These refer to the risk factors described in Stratiskin Sciences' most recently filed annual report on Form 10-K and subsequent periodic reports filed with the FCC and Stratiskin Sciences press release that accompanies this call, particularly the cautionary statements within. The content of this call contains time-sensitive information that is accurate only as of today, November 13, 2025. And except as required by law, Stratiskin Sciences disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It's now my pleasure to turn the call over to Dr. Doliv Raffaelli, CEO of Stratiskin Sciences. Doliv.

Thank you, Jules, and good afternoon to everyone on the call. During the third quarter of 2025, we continued to position our business for future growth and lasting shareholder value creation. Key to the progress will be the historic expansion of CPT codes for Stratas Extract 308 nanometer eczema laser, which are expected to become effective January 1st, 2027. As a reminder, the revision of these codes expands reimbursement eligibility for eczema laser treatments to include multiple inflammatory and autoimmune skin conditions beyond their original psoriasis indication, enabling coverage for conditions such as vitiligo, atopic dermatitis, mycosis fungoid, lichen planus, alopecia areata, and cutaneous T-cell lymphoma, better known as CTCL, among approximately 30 indications. The implication of these changes are pivotal to our future business and that of our partners as they Exponentially expand our opportunity to provide services to patients in need while creating a meaningful increase in potential revenue from procedures, which until now would not be within reach. While the revisions are set to go into effect on January 1, 2027, we have commenced the process to expand this change to private payers as well. The latest progress of the recognition of these expanded codes is the Centers of Medicare and Medicaid Services, or CMS, has recognized both the existing psoriasis-only codes and the expanded ones in its calendar year 2026 Medicare physician fee schedule final rule publication, which will then reflect into the 2027 reimbursement code. As we have previously indicated, these additional reimbursement codes open our addressable markets to over 30 million patients, expanding our total available markets by threefold. In addition, we have submitted economic data to support a potential increase in the reimbursement rate for each of our codes, which the CMS 2026 final rule has indicated will be reviewed for consideration. We've also continued to strengthen our practice partners through our Elevate360 consulting model and our innovative DTC campaign. Elevate360 focuses on improving utilization of the partner clinics by supporting the implementation of best practices to drive optimal use of extract lasers. Since the beginning of 2025, 99 of our approximately 838 clinics operating under our extract usage agreement have entered the Elevate360 program, which has resulted in an average of 7% growth year over year for those businesses. completing a review as a part of the program's design. Additionally, average gross billings per device for all 838 of our US partner clinics of $5,981 for the third quarter of 2025 increased 8.5% versus the third quarter of 2025 and represents the highest gross billings per device since the fourth quarter of 2022. Turning back to Elevate360, I want to share a specific example of a partner which began with two clinics in the first half of 2024, and after adopting the Elevate360 program, expanded to nine clinics and revenue contribution from the account increased tenfold. By providing deeper analytics, We help these partners better understand the financial opportunities associated with the patients they already see in their clinics and those they have prescribed but did not follow through with extra scheduling. We expect that these kinds of improvements will become exponential in the coming year with the addition of new reimbursement opportunities resulting from the expansion of indications for which extract treatment will become available. Turning to TheraClearX, while this remains a small but growing portion of our revenue, we reached an important milestone with the regulatory approval and subsequent initial commercial placement in Mexico. We believe the continued international expansion of both the EXTRACT and CeraClearX technologies represents significant opportunity for growth and value generation. During the third quarter, we continue to experience challenges in our international business, which we believe is attributable mainly to the current trade policy of the United States government. creating uncertainty and pressuring our total revenue for the quarter. Turning to litigation, we offered an update on our case against LaserOptic regarding its use of false and misleading statements in its marketing. We believe we are strongly positioned in this suit and have the potential to be awarded significant damages. An injunction issued late last year was very helpful in limiting any further damage to our domestic recurring business. We are pleased that the court agreed with our position that LaserOptic Korea, the parent of LaserOptic America, as well as another entity which was used as the face for LaserOptic's U.S. sales efforts, should be added as defendant. We believe this will result in our ability to collect damages. In the meantime, the injunction and clarity offered by the litigation allowed us to engage multiple dermatology clinics that had been previously misled by false claims about the Pallas solid-state lasers. To date, over 20 such laser optic buyers have partnered back with Strata under our program or have purchased extract eczema lasers directly from us, which represents more than $1 million in annual capital and recurring revenue, emphasizing extract as the recognized gold standard in the targeted UVB therapy. With that, I'd like to turn the call over to John Gillings, who will review our financial results in more detail. John?